Solvay Pharmaceuticals GmbH
Records under this name other than patents Solvay Pharmaceuticals GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Solvay Pharmaceuticals GmbH
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,072,256 | Process for Separating and Determining the Viral Load in a Pancreatin Sample Formerly held In force · High confidence | In force | High confidence | |
| US 8,273,348 | Lipase Variants for Pharmaceutical Use Formerly held In force · High confidence | In force | High confidence | |
| US 11,266,607 | Process for the Manufacture and Use of Pancreatin Micropellet Cores Formerly held In force · High confidence | In force | High confidence | |
| US 9,198,871 | Delayed Release Pancreatin Compositions Formerly held In force · High confidence | In force | High confidence | |
| US 7,232,813 | Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders Formerly held Term ended Term ended Jul 9, 2025 · USPTO record | Term ended | Term ended Jul 9, 2025 | USPTO record |
| US 8,802,087 | Pharmaceutical Compositions of Lipase-Containing Products, in Particular of Pancreatin Formerly held Term ended Term ended Mar 22, 2025 · High confidence | Term ended | Term ended Mar 22, 2025 | High confidence |
| US 7,479,378 | Method of analyzing enzyme compositions with lipolytic, proteolytic and amylolytic activity Term ended Term ended Sep 25, 2024 · USPTO record | Term ended | Term ended Sep 25, 2024 | USPTO record |
| US 8,138,174 | Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition Formerly held Lapsed on the fee record Ended Mar 20, 2024 · USPTO record | Lapsed on the fee record | Ended Mar 20, 2024 | USPTO record |
| US 7,202,238 | Diazabicyclo alkane derivatives with NK1 antagonistic activity Term ended Term ended Jan 25, 2024 · USPTO record | Term ended | Term ended Jan 25, 2024 | USPTO record |
| US 8,101,619 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition Lapsed on the fee record Ended Jan 24, 2024 · USPTO record | Lapsed on the fee record | Ended Jan 24, 2024 | USPTO record |